Download PDF
Thromb Haemost 1979; 41(02): 436-449
DOI: 10.1055/s-0038-1646792
Original Articles
Schattauer GmbH Stuttgart

Mode of Action of Ticlopidine in Inhibition of Platelet Aggregation in the Rat

Shin-Ichiro Ashida
The Laboratory of Biochemistry, Research Institute, Daiichi Seiyaku Co., Ltd. Tokyo 132, Japan
,
Yasushi Abiko
The Laboratory of Biochemistry, Research Institute, Daiichi Seiyaku Co., Ltd. Tokyo 132, Japan
› Author Affiliations
Further Information

Publication History

Received 10 February 1978

Accepted 19 May 1978

Publication Date:
09 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Ticlopidine, when orally administered to rats, resulted in activation of basal and prostaglandin E1 (PGE1)-stimulated adenylate cylase activity through increase in affinity of the cyclase in platelet membrane to PGE1, although it failed to affect adenosine- or sodium fluoride-stimulated activity of the enzyme. In washed platelets, Ticlopidine also activated basal and PGE1-stimulated activity of the cyclase and prevented reduction in the cyclase activity caused by low concentrations of PGE2. Furthermore, Ticlopidine inhibited malondialdehyde formation in platelets induced by thrombin but failed to inhibit that caused by exogenous arachidonic acid. Adenosine 3’,5’-cyclic monophosphate (c-AMP): phosphodiesterase activity of platelet lysate was not significantly affected by Ticlopidine treatment.

These findings indicate that Ticlopidine inhibits platelet aggregation and prostaglandin synthesis from endogenous substrate through activating basal and PGE1-stimulated activity of the cyclase, preventing PGE2-induced depression of the cyclase activity and thus increasing platelet c-AMP level.

 

  • References

  • 1 Ashida S, Abiko Y. 1979 Inhibition of platelet aggregation by a new agent, Ticlopidine. Thrombosis and Haemostasis.
    PubMedGoogle Scholar
  • 2 Ashida S, Abiko Y. 1978; Effect of Ticlopidine and acetyl-salicylic acid on generation of prostaglandin I2-like substance by rat arterial tissue. Thrombosis Research 13: 901
    CrossrefPubMedGoogle Scholar
  • 3 Ball G, Brereton GG, Fulwood M, Ireland DM, Yates P. 1970; Effect of prostaglandin E1alone and in combination with theophylline or aspirin on collagen-induced platelet aggregation and on platelet nucleotides including adenosine 3’,5’-cyclic monophosphate. Biochemical Journal 120: 709
    CrossrefPubMedGoogle Scholar
  • 4 Cole B, Robison GA, Hartmann RC. 1971; Studies on the role of cyclic AMP in platelet function. Annals of the New York Academy of Sciences 185: 327
    CrossrefPubMedGoogle Scholar
  • 5 Ebihara A, Aoki N, Sano M, Suzuki T. 1977; New antithrombotic drug, Ticlopidine: Phase I study in Japanese. Japanese Journal of Clinical Pharmacology 8: 63
    PubMedGoogle Scholar
  • 6 Flower RJ, Cheung HS, Cushman DW. 1973; Quantitative determination of prostaglandins and malondialdehyde formed by the arachidonate oxygenase (prostaglandin synthetase) system of bovine seminal vesicle. Prostaglandins 4: 325
    CrossrefPubMedGoogle Scholar
  • 7 Gordon JL, Macintyre DE, Mcmillan RM. Malondialdehyde production and the release reaction in rat blood platelets: inhibition by aspirin and indomethacin ex vivo. In: Abstracts, Proceedings of the British Pharmacological Society. 15.07.1976; 299 p
    PubMedGoogle Scholar
  • 8 Hamberg M, Samuelsson B. 1974; Prostaglandin endoperoxides: Novel transformation of arachidonic acid in human platelets. Proceedings of the National Academy of Science, USA 71: 3400
    CrossrefPubMedGoogle Scholar
  • 9 Hamberg M, Svensson J, Samuelsson B. 1974; Prostaglandin endoperoxides: A new concept concerning the mode of action and release of prostaglandins. Proceedings of the National Academy of Science, USA 71: 3824
    CrossrefPubMedGoogle Scholar
  • 10 Haslam RJ, Lynham JA. 1972; Activation and inhibition of blood platelet adenylate cyclase by adenosine or by 2-chloroadenosine. Life Sciences 11: 1143
    CrossrefPubMedGoogle Scholar
  • 11 Haslam RJ, Rosson GM. 1975; Effect of adenosine on levels of adenosine cyclic 3’,5’-monophosphate in human blood platelets in relation to adenosine incorporation and platelet aggregation. Molecular Pharmacology 11: 528
    PubMedGoogle Scholar
  • 12 Krishna G, Weiss B, Brodie BB. 1968; A simple, sensitive method for the assay of adenylcyclase. Journal of Pharmacology and Experimental Therapeutics 163: 379
    PubMedGoogle Scholar
  • 13 Kunitada S, Honma M, Ui M. 1978; Increases in plasma cyclic AMP dependent on endogenous catecholamines. European Journal of Pharmacology 48: 159
    CrossrefPubMedGoogle Scholar
  • 14 Lapetina EG, Schmitges CJ, Chandrabose K, Cuatrecasas P. 1977; Cyclic adenosine 3’,5’-monophosphate and prostaglandin inhibit membrane phospholipase activity in platelets. Biochemical and Biophysical Research Communications 76: 828
    CrossrefPubMedGoogle Scholar
  • 15 Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. 1951; Protein measurement with the folin phenol reagent. Journal of Biological Chemistry 193: 265
    PubMedGoogle Scholar
  • 16 Macintyre DE, Gordon JL. 1975; Calcium-dependent stimulation of platelet aggregation by PGE2 . Nature 258: 337
    CrossrefPubMedGoogle Scholar
  • 17 Maffrand JP, Eloy F. 1974; Synthesis de thiénopyridine et de furopyridines d’intérêt thérapeutique. European Journal of Medicinal Chemistry 9: 483
    PubMedGoogle Scholar
  • 18 Maguire ME, Sturgill TW, Gilman AG. 1975; Frustration and adenylate cyclase. Metabolism 24: 287
    CrossrefPubMedGoogle Scholar
  • 19 Malmsten C, Granstrom E, Samuelsson B. 1976; Cyclic AMP inhibits synthesis of prostaglandin endoperoxide (PGG2) in human platelets. Biochemical and Biophysical Research Communications 68: 569
    CrossrefPubMedGoogle Scholar
  • 20 Mills DC B, Macfarlane DE. 1974; Stimulation of human platelet adenylate cyclase by prostaglandin D2 . Thrombosis Research 5: 401
    CrossrefPubMedGoogle Scholar
  • 21 Mills DC B, Smith JB. 1971; The influence on platelet aggregation of drugs that affect the accumulation of adenosine 3’,5’-cyclic monophosphate in platelets. Biochemical Journal 121: 185
    CrossrefPubMedGoogle Scholar
  • 22 Minkes M, Stanford N, Chi MM Y, Roth GJ, Raz A, Needleman P, Majerus PW. 1977; Cyclic adenosine 3’,5’-monophosphate inhibits the availability of arachidonate to prostaglandin synthetase in human platelet suspensions. Journal of Clinical Investigation 59: 449
    CrossrefPubMedGoogle Scholar
  • 23 O’Brien JR. 1968; Effects of salicylates on human platelets. Lancet 1: 779
    PubMedGoogle Scholar
  • 24 Oelz O, Oelz R, Knapp HR, Sweetman BJ, Oates JA. 1977; Biosynthesis of prostaglandin D2 . 1. Formation of prostaglandin D2by human platelets Prostaglandins 13: 225
    CrossrefPubMedGoogle Scholar
  • 25 Podesta M, Aubert D, Ferrand JC. 1974; Contribution à l’étude pharmacologique de thiénopyridines et d’analogues furanniques. European Journal of Medicinal Chemistry 9: 487
    PubMedGoogle Scholar
  • 26 Roth GJ, Stanford N, Majerus PW. 1975; Acetylation of prostaglandin synthetase by aspirin. Proceedings of the National Academy of Science, U.S. A., 72: 3073
    PubMedGoogle Scholar
  • 27 Salzman EW. 1972; Cyclic AMP and platelet function. New England Journal of Medicine 286: 358
    CrossrefPubMedGoogle Scholar
  • 28 Salzman EW, Kensler PC, Levine L. 1972; Cyclic 3’, 5’-adenosine monophosphate in human blood platelets. IV. Regulatory role of the cyclic AMP in platelet function Annals of the New York Academy of Sciences 201: 61
    CrossrefPubMedGoogle Scholar
  • 29 Smith JB, Willis AL. 1970; Formation and release of prostaglandin by platelets in response to thrombin. British Journal of Pharmacology 40: 545
    PubMedGoogle Scholar
  • 30 Smith JB, Ingerman C, Kocsis JJ, Silver MJ. 1973; Formation of prostaglandins during the aggregation of human blood platelets. Journal of Clinical Investigation 52: 965
    CrossrefPubMedGoogle Scholar
  • 31 Smith JB, Ingerman CM, Silver MJ. 1976; Malondialdehyde formation as an indicator of prostaglandin production by human platelets. Journal of Laboratory and Clinical Medicine 88: 167
    PubMedGoogle Scholar
  • 32 Smith JB, Silver MJ, Ingerman CM, Kocsis JJ. 1974; Prostaglandin D2inhibits the aggregation of human platelets. Thrombosis Research 5: 291
    CrossrefPubMedGoogle Scholar
  • 33 Stuart MJ, Murphy S, Oski FA. 1975; A simple nonradioisotope technic for the determination of platelet life span. New England Journal of Medicine 2921: 1310
    PubMedGoogle Scholar
  • 34 Thebault JJ, Blatrix CE, Blanchard JF, Panak EA. 1975; Effects of Ticlopidine, a new platelet aggregation inhibitor in man. Clinical Pharmacology and Therapeutics 18: 485
    PubMedGoogle Scholar
  • 35 Villa S, Callioni A, De Gaetano G. 1977; a Normal prostacyclin-like activity in vascular tissues from thrombocytopenic rats. Thrombosis Research 11: 701
    CrossrefPubMedGoogle Scholar
  • 36 Villa S, Mysliwiec M, De Gaetano G. 1977; b Prostacyclin and atherosclerosis in rats. Lancet 1: 1216
    PubMedGoogle Scholar
  • 37 Willis AL, Vane FM, Kuhn DC, Scott CG, Petrin M. 1974; An endoperoxide aggregator (LASS) formed in platelets in response to thrombotic stimuli: Purification, identification and unique biological significance. Prostaglandins 8: 453
    CrossrefPubMedGoogle Scholar